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INTRODUCTION
Complex regional pain syndrome (CRPS) refers to a chron-
ic pain condition associated with autonomic disturbances of
vasomotor and sudomotor origin (1), along with trophic skin
changes and patchy demineralization of the bones (2). Alth-
ough the mechanism for CRPS has not been elucidated, stud-
ies indicate that it is a complex disorder involving both the
central and peripheral nervous systems (3, 4). This complex
etiology of CRPS is manifested by its heterogeneous constel-
lation of clinical symptoms. In the acute stages, hallmarks in-
clude mechanical hyperalgesia, edema, increased sweating skin
temperature, and hair growth (5). After some time, CRPS
symptoms progress to a cold stage, with decrease of skin tem-
perature, formation of skin atrophy and bony osteoporotic ch-
anges (6). CRPS pathogenesis is heterogeneous and complex,
which makes its treatment challenging.
Pharmacological therapy for CRPS includes a wide array
from anti-inflammatory drugs, systemic corticosteroids (7),
antidepressants, opioids (8) to bisphosphonate agents (9-12).
However, there is yet no single pharmacological agent or trea-
tment algorithm that can resolve all of its heterogenic features.
The efficacy for most pharmacological agents remains largely
empirical, with the exception of bisphosphonate agents, which
are the only agents with proven efficacy for CRPS based on
multiple controlled trials (8-13). 
Bisphosphonates are antiresorptive agents, which are used
in osteoporosis and other bone conditions such as tumor-indu-
ced hypercalcemia. The use of bishphosphonate agents in CR-
PS are widely supported for their efficacy of pain, but some
clinical studies have also suggested efficacy for edema (9) and
joint mobility (10). However, despite the extensive research-
es on bisphosphonate agents, there are no definite guidelines
that recommend the routine use of bisphosphonate for CRPS.
This is due to a lack of specific standardized treatment regi-
mens and scant clinical data on the optimum dosage, frequ-
ency and duration of treatment to cover the heterogenic
features of CRPS. Previous animal studies have shown that
alendronate, a bisphosphonate agent, showed analgesic effects
only with high dosage supplementation  (14, 15). 
To determine on the optimal dosage and administration sc-
hedule of bisphophonate in CRPS, further studies are warrant-
ed on the effective administration schedule and dosages of bis-
phophonate that target various symptoms, including autono-
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Effective Dosage and Administration Schedule of Oral Alendronate for
Non-nociceptive Symptoms in Rats with Chronic Constriction Injury 
We evaluated the efficacy of oral alendronate with different dosing regimens for non-
nociceptive symptoms and osteoporosis in a sciatic nerve chronic constriction injury
(CCI) model. Male Sprague-Dawley rats (n=60) were subdivided into sham control
(SC) group and CCI groups, which were divided according to dosage and time of oral
alendronate administration: no treatment (NT), low dosage early (LE), high dosage
early (HE), low dosage late (LL) and high dosage late (HL). We measured the thick-
ness and temperature of the hind paw, bone mineral density (BMD) of the tibia, al-
ong with tibia bone strength. On the 14th day post-CCI, the HE group showed sig-
nificant reduction in thickness and temperature (P<0.001). On the 42nd day post-
CCI, the HE group showed significant reduction in temperature compared to the NT
group (P<0.001). Also, both HE and HL groups showed statistically significant incr-
eased tibia BMD (P<0.001), along with increase of tibia bone strength compared to
the NT group. Based on these findings, early alendronate in high dosages is effec-
tive in the non-nociceptive symptoms; early and late alendronate in high dosages,
are effective in preventing bone dystrophic changes in a CCI model. 
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mic and bone dystrophic changes. Therefore, in order to deter-
mine a proper dosing regimen of bisphosphonate agents in
CRPS, this study was carried out with the following aims;
first, to determine the efficacy of oral alendronate, a bisphos-
phonate agent, on non-nociceptive symptoms, namely, on ede-
ma, skin temperature and bone dystrophic changes, using a
Sprague-Dawley rat model of chronic constrictive injury (CCI)
to represent CRPS, and second, to determine if these effica-
cies varied with different dosing regimens and time of admin-
istration.
MATERIALS AND METHODS
Animals
Sixty male Sprague-Dawley rats with a mean weight of
347 g were used in the present study. Animals were purchas-
ed from the Orient Bio Company (Seongnam, Korea). All
experimental procedures were approved by the Institutional
Animal Care and Use Committee of the Catholic University
(Approval number CUMC-2009-0096-01). Rats were ran-
domly divided into 6 groups: a sham control group (SC) and
5 CCI groups. CCI groups were divided according to dosage
and time of bisphosphonate administration: no treatment
(NT), low dosage early treatment (LE), high dosage early treat-
ment (HE), low dosage late treatment (LL) and high dosage
late treatment (HL) bisphosphonate groups. Each group con-
sisted of 10 rats. 
Induction of CCI
All rats were anesthetized by injecting 1% ketamine (30
mg/kg body weight) and xylazine hydrochloride (4 mg/kg
body weight). The temperature during surgery was mainta-
ined at 37±1℃ CCI was induced according to the proce-
dure previously described by Bennett and Xie (16). Sham-
operated rats that served as controls (SC) underwent the same
surgical procedure with sciatic nerve exposure, but without
sciatic nerve ligation. Animals were allowed to recover from
anesthesia and surgery. One animal per cage was housed with
free access to water and standard laboratory chow.
Drug administration 
Alendronate sodium (FOSAMAX
®, Merck & Co. Inc., Wh-
itehouse Station, NJ, USA) was prepared in powder form, di-
ssolved in saline, and was administered into the oral cavity
once a day via a tube. Alendronate sodium was administered
at the same time every day. The 2 early treatment groups (HE,
LE) were treated immediately after surgery for 6 weeks. Late
treatment groups (HL, LL) were treated starting at the 14th
day after CCI for 4 weeks. We chose the 14th day to catego-
rize those into early (HE, LE) and late (HL, LL) groups bas-
ed on results from Suyama et al. (17) who showed that bone
mineral density (BMD) significantly decreased from the sec-
ond week after CCI.
For the low dosage groups (LE, LL), 0.1 mg/kg/day was
administered (18). For the high dosage groups (HE, HL), 1
mg/kg/day was administered along with sufficient water (19,
20). When the other groups received alendronate, we provid-
ed to the SC and NT groups, the same amount of saline via
the same route. Similarly, we provided to the LL and HL gr-
oups the same amount of saline via the same method during
the first 2 weeks after CCI, when these 2 groups were not eli-
gible to receive alendronate administration. In order to reduce
potential bias, we ensured that the examiner who provided
alendronate or saline was blinded to the procedures performed
and amount of alendronate administered to the rats.
Evaluation of vasomotor and sudomotor symptoms,
measurement of dorsal-ventral thickness of the hind paw
and temperature of the hind paw dorsum 
To confirm the aptness of the CCI model and to examine
the effects of alendronate therapy on CRPS-related symptoms,
sudomotor function was evaluated by temperature measure-
ment of the right hind paw dorsum using a digital infrared
thermometer (OPTEX Co., Shiga, Japan) according to a me-
thod previously described (21). To evaluate vasomotor func-
tion, edema of the dorsal-ventral thickness of the right hind
paw was measured using a manual mobile caliper. During the
experiment, all measurements were performed 3 times: on the
day prior to, the 14th and 42nd day after CCI.
Evaluation of bone metabolism; BMD and bone strength 
Prior to CCI, 14th and 42nd day after-CCI, BMD measur-
ements were performed on the right tibia for all 6 groups us-
ing Dual Energy radiography Absortiometry (Hologic Inc.,
Bedford, MA, USA), which was equipped with a program to
evaluate BMD for rats. BMD measurement was carried out
according to the methods recommended by previous studies
(22, 23).
After the rats were sacrificed on the 42nd day after surgery,
we removed the right tibia and measured bone strength for
all 6 groups. The measurement used a 3-point system and
the strength against physical force was measured using an
Imperial
TM 1000 (Mecmesin Limited, Slinford, UK) accord-
ing to the methods used in other studies (23). 
Statistical analysis
We presented our results in means±standard deviations.
We evaluated all data using the Kruskal-Wallis test followed
by Mann-Whitney test with Bonferroni’s correction using
SPSS 11.0 for Windows. All tests were two-tailed, and P
values <0.05 were considered statistically significant.T
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Fig. 2. Efficacy of oral alendronate in different dosage and time of
administration in skin temperature of the affected hind-paw from
Sprague-Dawley rats. 
*P<0.001 as compared with NT group; 
� P<0.001 as compared
with SC group.
CCI, chronic constriction injury; SC, sham control; NT, no treatment;
LE, low dosage early treatment; HE, high dosage early treatment;
LL, low dosage late treatment; HL, high dosage late treatment.
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Fig. 1. Efficacy of oral alendronate in different dosage and time of
administration in dorsal-ventral thicknesses of the affected hind-
paw from Sprague-Dawley rats.  
*P<0.001 as compared with NT group; 
� P<0.001 as compared
with SC group. 
CCI, chronic constriction injury; SC, sham control; NT, no treatment.
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RESULTS
All rats survived to the completion of the experiment, ex-
cept for 1 case in the SC group, which died during the pro-
cedure. Data from a total of 59 rats were analyzed. All data
for hind paw thicknesses, skin temperature, BMD and bone
strength measured prior to, and on 14th, 42nd day post-CCI
are presented in Table 1.
General observations
The CCI rats exhibited typical pain-related pain behaviors
and these were similar in nature to those previously described
by Bennett and Xie (16). Pain-related behaviors, such as, lim-
ping, abnormal hindpaw clawing, and guarding at the CCI
side were observed in a consistent manner in all CCI groups.
None of the SC rats showed these abnormal pain related beha-
viors, and these were consistent to findings reported from
other studies (16, 17). 
Dorsal-ventral thickness of right hind paws 
Prior to CCI, no significant differences of hindpaw thick-
ness were detected between groups (Fig. 1). Fourteen days
after CCI, the thicknesses of the hind paws for 5 CCI groups
were significantly thicker than that of the SC group. Thick-
nesses for the HE and SC group were significantly reduced
than that of the NT group (P<0.001). Forty two days after
CCI, only the SC group showed significantly reduced thick-
ness than that of the NT group. Also, thicknesses of hind pa-
ws for the 2 low dosage treatment (LE and LL) groups and
NT were significantly thicker than that of the SC group. The 2
*P<0.001 as compared with the NT group; 
� P<0.001 as compared with the SC group.
BMD, bone mineral density; CCI, chronic constriction injury; SC, sham control; NT, no treatment; LE, low dosage early treatment; HE, high dosage early
treatment; LL, low dosage late treatment; HL, high dosage late treatment.
Hindpaw dorsal ventral thickness (mm) Skin Temperature (°C) BMD tibia (g/cm
2)
CCI Prior  Post 14th day  Post 42nd day  Prior  Post 14th day  Post 42nd day  Prior  Post 14th day  Post 42nd day 
SC 3.6±0.2 3.8±0.2* 4.1±0.4* 33.1±3.0 28.7±1.0* 31.1±2.2* 0.079 ±0.004 0.088±0.006 0.091±0.004*
NT 3.5±0.2 4.9±0.3
� 5.2±1.3
� 33.8±2.0 32.0±1.4
� 33.6±0.7
� 0.083±0.003 0.084±0.003 0.078±0.006
�
LE 3.5±0.1 5.9±1.3
� 5.2±0.9
� 33.3±1.0 34.0±1.8
� 33.6±1.0
� 0.082±0.006 0.082±0.008 0.089±0.007
HE 3.7±0.2 4.4±0.2*
,� 4.9±1.0 34.1±1.6 29.8±1.1* 32.2±1.1* 0.078±0.008 0.085±0.006 0.097±0.012*
LL 3.6±0.1 4.9±0.3
� 5.0±0.6
� 34.1±0.7 34.5±0.6
� 34.8±0.6
� 0.084±0.003 0.083±0.004 0.078±0.008
�
HL 3.6±0.2 5.2±0.2
� 4.6±0.4 33.6±1.6 34.6±1.2
� 31.9±1.8 0.081±0.004   0.087±0.005 0.089±0.011*
Table 1. Hindpaw dorsal ventral thickness, skin temperature, and tibia BMD from Sprague-Dawley rats, measured prior to, and 14th
and 42nd days after CCI. All data are presented as mean±standard deviationOral Alendronate in CCI  941
high dosage groups (HE, HL) did not show statistically signif-
icant difference of thickness (Table 1) in comparison to NT
group.
Skin temperature of right hind paws
Prior to CCI, no significant difference of right hindpaw skin
temperature was detected between groups (Fig. 2). Fourteen
days after CCI, the temperatures of all CCI groups, except the
HE group, were significantly elevated than that of the SC
group (P<0.001). Temperatures of HE and SC group were
significantly reduced than that of the NT group (P<0.001).
Similarly, forty two days after CCI, the temperatures of the
HE and SC group were significantly reduced than that of the
NT group (P<0.001); also the temperatures of the LE, LL and
NT groups were significantly elevated versus the SC group
(P<0.001) (Table 1).
Bone metabolism
Prior to, and 14 days after CCI, tibia BMD showed no sig-
nificant differences between groups (Fig. 3). Forty two days
after CCI, tibia BMDs of the 2 high dosage and SC group
were higher than that of the NT group (P<0.001). BMDs
of tibia for the NT and LL group were significantly reduced
than that of the SC group (P<0.001) (Table 1). 
Bone strengths were measured after sacrificing the rats on
the 42nd day post-CCI, and these values for the SC, NT, LE,
HE, LL and HL groups were 69.7±9.6N, 62.8±4.2N,
69.2±10.0N, 70.7±8.1N, 64.2±6.4N, and 70.8±5.8N,
respectively. Bone strength values of the 2 high dosage groups
(i.e., HE and HL) were significantly higher than that of the
NT group (P<0.05) (Fig. 4).
DISCUSSION 
The results from the present study show that efficacy of ale-
ndronate in non-nociceptive symptoms varies with different
doses and times of administration in a rat model of CCI. The
results of the present are in accordance to those from previous
findings (24) that bisphosphonates are effective in vasomotor,
sudomotor and bone dystrophic changes. In addition, our re-
sults provide new information on the dosage and time admin-
istration that are effective for these non-nociceptive symp-
toms. For hindpaw thickness and temperature, we detected
significant efficacy of early and high dosage alendronate. For
BMD and bone strength, we detected significant efficacy of
high dosage alendronate, with both early and late adminis-
tration. In sharp contrast, we were not able to detect these
significant efficacies with low dosage alendronate adminis-
tration. From these results, we recommend that high dosage
oral alendorate administered in the early stages is effective to
cover the heterogenic features of CRPS in a CCI-rat model.
Previous clinical studies showed that bisphophonates helped
to relieve some symptoms related to edema. Adami et al. (9)
showed that intravenous alendronate resulted in improveme-
nts for edema, as well as pain, although their results were lim-
ited by a short follow-up period. Another study (10) showed
that high dosage oral alendronate resulted in statistically sig-
nificant reductions of swelling at 4 weeks. But, similar to our
results, this efficacy was not sustained at later periods. In the
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Fig. 3. Efficacy of oral alendronate in different dosage and time of
administration in BMD of the affected tibia from Sprague-Dawley
rats. 
*P<0.001 as compared with the NT group; 
� P<0.001 as com-
pared with the SC group. 
BMD, bone mineral density; CCI, chronic constriction injury; SC,
sham control; NT, no treatment; LE, low dosage early treatment;
HE, high dosage early treatment; LL, low dosage late treatment;
HL, high dosage late treatment. 
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Fig. 4. Efficacy of oral alendronate in different dosage and time of
administration in bone strength of the right tibia from Sprague-Da-
wley rats, obtained after the rats were sacrificed. 
*P<0.05 as compared with the NT group.
CCI, chronic constriction injury; SC, sham control; NT, no treat-
ment; LE, low dosage early treatment; HE, high dosage early
treatment; LL, low dosage late treatment; HL, high dosage late
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early stages of clinical CRPS, cutaneous vasodilatation is par-
ticularly prominent. However in later stages, as CRPS progr-
esses to a cold stage, vasoconstriction predominates and swel-
ling becomes less prominent. This typical cold stage progres-
sion should offer a possible hypothesis on why, despite the high
dosage, we did not observe statistically significant reduction
of skin thickness in the late administration groups and why
we detected these changes only on the 14th day post-CCI in
the HE group. Based on our results, we postulate that as CRPS
progressed to a cold stage, efficacy of early high dosage admin-
istration of oral alendronate was not sustained in these late
stages and that efficacy of late alendronate administration,
regardless of dosage, was limited. 
In contrast, for temperature, we observed that the positive
effects of early high dosage alendronate were sustained with
follow-up observation on the 42nd day post-CCI. Unfortu-
nately, based on the present results alone, we were unable to
come up with a suitable explanation for these different resp-
onses in temperature and we agreed that this was a topic that
calls for future researches. Nevertheless, our results indicated
that early high dosage alendronate supplementation should
help alleviate the swelling and elevated temperature which
predominated the acute stages of CRPS. The use of glucocor-
ticoid therapy could be an alternative method to compensate
for the limited efficacy of alendronate for the autonomic sym-
ptoms in the later stages of CRPS. Glucocorticoid therapy was
reported to show sustained efficacy after long term follow-up
by modulating de novo protein biosynthesis (25). 
The exact action of alendronate for CRPS, especially for
swelling and increased temperature, is still under debate, but a
recent study of ibandronate, a potent bisphosphonate agent,
showed that its effects were chiefly mediated by modulating
substance P (24). Substance P is a neuropeptide that binds to
NK1 receptors of postcapillary venules and causes albumin
and protein extravasations. Schinkel et al. (26) pointed that
the increased activity of this neuropeptide, which was elevat-
ed in serum samples in CRPS patients, was responsible for the
increase of skin temperature and edema. We postulate that
the mechanism of high dosage alendronate to control swelling
and increased temperature was through modulation of this
substance P. Nevertheless, the results of the present study
could be supported by direct quantification of substance P
and other neuropeptides. 
Patchy demineralization with bone loss and osteoporosis
in the affected limb are postulated to occur due to increased
osteoclast activities. Also alendronate administration has been
shown to be effective to reverse this CCI-induced bone loss.
Whereas edema and vasomotor symptoms are predominant
features of acute CRPS, bone loss is a predominant feature of
chronic CRPS. BMD in CCI rats show significant decrease
from two weeks after CCI (17), also this loss persists for at
least 20 weeks after sciatic nerve resection (27). Likewise, bone
density loss progresses over several months after injury in clin-
ical CRPS. We suggest that it was due to this reason, that we
detected significant efficacy in bone metabolism for the high
dosage group even with late administration, and that we detect-
ed this efficacy with further follow-up on the 42nd day post-
CCI. This sustained efficacy of the high dosage groups was
again confirmed through our measurements of the tibia stre-
ngth, which, similar to the results for BMD, showed preserv-
ed values after the rats were sacrificed. 
Previous animal studies have shown that alendronate had
analgesic effects only with high dosage (14, 15). The present
results were in accordance with those studies, and showed sta-
tistically significant responses in non-nociceptive symptoms
only in the high dosage groups. In addition, this is the first
report, according to our knowledge, that has associated vari-
able efficacy of a bisphopshonate agent with different dosages
and time of administration across various symptoms in a CCI
model. However, in order to translate our findings to clini-
cal practice, there is a need to define a corresponding dose
for humans that correlates to the high dosage used in this
study. The 1.0 mg/kg/day dosage administered to the high
dosage groups is equal to that used in previous studies (19,
20), but is approximately 5-6 times higher than standard clin-
ical dosages. Thus, the high dosage used in our study poses
potential problems for direct administration to humans. Con-
tinuous clinical studies to determine an appropriate human
dosage are needed.
Some limitations of this study need to be considered. First,
previous studies (14, 15) showed that alendronate shows noci-
ceptive effects only at high dosages. However, pain was not
directly assessed in our CCI model, because the main focus
of this paper was to assess alendronate efficacy in non-noci-
ceptive symptoms. Nevertheless, we indirectly observed some
pain-related abnormal behavior patterns in the CCI groups
as previously reported (3, 17). In addition, we observed that
the high dosage alendronate groups recovered from these pain-
related behaviors sooner than the  NT or low dosage groups.
However, we were unable to determine from these observa-
tions if these pain responses differed between those with early
or late alendronate administrations. The results of this study
could be supplemented with future studies that relate these
autonomic symptoms to pain. Second, oral bisphosphonate
agents have low absorption rates and their analgesic efficacy
is questionable when compared to intravenous bisphospho-
nate agents with higher potencies. However, oral administra-
tion may be preferred in clinical practice because of its low
cost (10) and safe side effect profile. High dosage intravenous
bisphosphonate administration has been associated with some
severe side effects. Moreover, Manicourt et al. (10) have shown
that oral alendronate in high dosages was effective for CRPS-
related hyperalgesia. Third, although we observed some vari-
ations within the groups across the follow-up time interval,
we did not compare these changes to the contralateral side
since the main scope of this study was to make comparison
between different doses and administration groups and deter-
mine which group shows the best efficacy. The variation oftemperature within the groups across the followup interval
could have been affected by the environment setting; tem-
perature measurement is sensitive to environmental fluctua-
tions. Therefore, in order to further prove the efficacies shown
in the present study and exclude any environmental factor,
further parameter measurements of the contralateral side at
each follow-up assessment would be warranted in future stud-
ies. Finally, various other models (28, 29) have been intro-
duced to be representative animal models for CPRS and some
may question the validity of the CCI model used in this study.
However, many studies (4, 30) showed that the CCI model,
first introduced by Bennett and Xie (16), is reliable for the
investigation of CRPS pathophysiology, and that it reproduced
well the increase of skin flow and temperature typically seen
in CRPS. Daemen et al. (3, 30) showed the role of inflamma-
tory reactions of CRPS with a CCI model, while others used
to this model to show the osteopathic changes of CRPS (17).
For these reasons, the authors considered that the CCI model
was adequate to represent CPRS for this study. 
Previous studies (8-13) failed to report if analgesic effects
differed between early and late alendronate administrations.
However, they have noted that patients show heterogeneous
responses, with large inter-individual responses, depending
upon disease duration. According to our results, non-nocicep-
tive symptoms responded to alendronate therapy other than
hyperalgesia in a variable manner, and these positive effects
were most apparent at a period when these symptoms are clin-
ically most profound in CRPS. Our results have important
clinical implications in the treatment of CPRS because they
show that high dosage bisphosphonate treatment was effec-
tive to control the increased swelling, temperature and bone
dystrophic changes of CRPS. Also, our results showed that
different efficacies could be expected with early and late alen-
dronate therapy. Whereas only early high dosage was effec-
tive to cover the autonomic features, high dosage alendronate
was effective to cover the bone dystrophic changes, regardless
of time of administration. As stated earlier, there are yet no
established guidelines on the appropriate dosage and time
of drug administration to cover the heterogenic features of
CRPS. The clinical relevance of our present study should be
supported with further clinical studies of alendronate. 
In summary, our results showed that oral alendronate in
high dosages was effective in non-nociceptive CRPS symp-
toms and that variable efficacy was observed with different
time of administration. These results may help guide future
clinical studies to establish the optimal dose and treatment
regimens that guarantee the best therapeutic responses of bis-
phosphonate agents across the heterogenic clinical features
of CRPS.
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